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The development of a flow cytometric method to detect the presence of 
mutated nucleophosmin in Acute Myeloid Leukaemia 
LA Du Pisani; K Shires – National Health Laboratory Service – Groote Schuur 
and the University of Cape Town 
Background: 
Nucleophosmin (NPM1) is an acidic, nucleo-cytoplasmic, shuttling protein with 
predominant nucleolar localisation that plays multiple roles in cell growth and 
proliferation. Deletion insertion mutations of NPM1 (NPM1 DIM) seem to disrupt 
it normal physiologic role as a molecular chaperone, which likely leads to its 
oncogenic potential.NPM1 if present alone (not associated with FLT3 internal 
tandem duplications (FLT3-ITD)) is associated with significantly better overall 
survival and disease free survival in AML and has been entered as a provisional 
category in the World Health Organisation (2008) classification of Acute Myeloid 
Leukaemia with recurrent genetic abnormalities. Current methodology uses 
reverse transcriptase polymerase chain reaction (RT-PCR) and genomic 
deoxyribonucleic acid (DNA) PCR techniques to detect NPM1 DIM. Although 
these methods are robust and relatively easy to perform they can be expensive, 
labour intensive and not universally available. Six major variants of NPM1 DIM 
(Types A-F) have been described all leading to frame shift. All six types share 
the same last five amino acids in the C-terminal.The aim of this study was to 
develop a robust flow cytometry methodology that could be used in the routine 
assessment of AML samples to determine the mutational state of NPM, using a 
commercially available polyclonal antibody against the mutated NPM1. 
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Methods: 
A commercially available NPM1 mutation specific antibody was used to develop 
a diagnostic method by flow cytometry. The antibody is polyclonal and of rabbit 
origin but is unconjugated. A secondary antibody, Alexafluor 488 goat anti-
rabbit, was used to detect the primary antibody binding. Cells were first labeled 
on the surface with CD45 PerCP for the purpose of gating. Red cells were lysed 
using FACS Lyse and the specimen was permeabilised using FACS PERM 
(Becton-Dickinson). Optimal antibody concentration, blocking technique for non-
specific binding as well as intracellular staining methodology was established. 
Flow cytometry was performed using a BD FACS Canto II flow cytometer and 
gating was performed on CD45 expression and side scatter. The technique was 
tested on a commercial cell line, OCI/AML3, with a known Type A NPM1DIM. 
The NPM1 mutation was confirmed on PCR. The minimum detectable 
concentration of NPM1 mutated cells was determined by doing dilution studies 
with normal peripheral blood. Samples from twelve newly diagnosed AML 
patients were used to correlate the NPM1 flow cytometry assay with DNA based 
PCR. Analysis was performed using Kaluza™ software. Median Fluorescence 
Intensity ratio (patient : negative control) of greater than 1.8 was established to 
optimally differentiate positive and negative patients on flow cytometry. 
6 
Results: 
The flow cytometric technique effectively detected the presence of mutant NPM1 
protein in the positive cell line with minimal non-specific binding when using an 
optimised intracytoplasmic staining and blocking technique as well as antibody 
concentration. Flow cytometry was able to detect blast populations of just less 
than 10% on dilution studies. Two of the twelve patients showed NPM1 DIM on 
both flow and PCR and ten were negative.  
Conclusions: 
Flow cytometry may be utilised as a relatively cost effective, rapid alternative to 
PCR to test for NPM1 DIM and may be applicable to laboratories that do not 
have access to molecular services however continued validation of this 
technique is required. 
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PART A: RESEARCH PROTOCOL 
Principle investigator 
Name:  Karen Shiresa 
HPCSA Registration number:  MW0010197 
University of Cape Town – Department of Haematology 
Project leader 
Name: Louis Almero Du Pisani 
Degree registered: Masters in medicine 
Year initially registered: 2006 (January) 
Project title 
Developing a novel flow cytometric method for determining the mutational status 
of Nucleophosmin (NPM1) in Acute Myeloid Leukaemia (AML) 
Short description of project 
This project aims to develop a simple method using flow cytometry to determine 
the mutational status of NPM1 in AML patients, by specifically detecting the 
mutated carboxy-terminal of this protein, using a mutation specific antibody. This 
may then in future form part of the standard antibody panel for Acute 
Leukaemia, as it has established prognostic significance. 
aPrinciple investigator was changed from Maureen Stein (due to resignation from 
NHLS) to Karen Shires (see collaborators)  
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Collaborators 
Prof. N. Novitzky 
University of Cape Town - Head of Division of Haematology 
Project 
Aims & Objectives 
Develop and validate a simple, cost effective, novel method using flow cytometry 
to determine the mutational status of NPM1. This aim will be achieved through 
the following objectives: 
a) Establish flow cytometry analysis of NPM1 molecules, using a NPM1
mutated specific antibody conjugated to FITC and a NPM1 mutant
control.b
b) Establish the methodology for the DNA based PCR analysis of NPM1
mutations, which is currently the most widely used technique, using a
positive control cell line. This will serve as a comparison to the new flow
cytometry method.c
c) Flow cytometry and PCR analysis of NPM1 will be conducted on various
routine patients’ samples with newly diagnosed AML   to establish the
validity of this novel method. Results will also be correlated with
cytogenetic results were appropriate.
bConjugating the mutated NPM1 specific antibody was cost prohibitive and 
would have created stability problems for storage of the antibody after 
conjugation. It was therefore decided to rather use a secondary antibody to 
detect the primary one. 
cPCR was performed at Groote Schuur Hospital NHLS laboratory 
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d) Background
NPM1: Wild type normal physiological function 
NPM1 is an acidic, nucleo-cytoplasmic, shuttling protein with predominant 
nucleolar localisation that plays multiple roles in cell growth and proliferation. In 
general the expression level is proportional to the cell growth rate (review) [1]. 
One of its roles is as a molecular chaperone that prevents protein aggregation in 
the nucleolus [2]. It also regulates the assembly and transport of pre-ribosomal 
particles through the nuclear membrane [3] thus playing a role in ribosomal 
biogenesis. Regulation of p14-Alternate reading frame (ARF) p53 pathway also 
takes place [4]. ARF is regulated by NPM1 in the nucleus. During oncogenic 
stress NPM1 is up regulated thus causing accumulation of ARF. The function of 
ARF is to stabilise Murine double minute 2 (MDM2) and thus prevent its 
attachment and destruction of p53 [5,6] over all leading to increased p53 and 
cell cycle arrest (see fig. 1). NPM1 initiates centrosome duplication and thus 
assists in mitosis [7]. 
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Figure 1.NPM over expression in tumour cells leads to increased proliferation and 
inhibition of apoptosis. (Reproduced from Nature Reviews Cancer, 2006) [8] 
a) In normally proliferating tissues, nucleophosmin (NPM) is expressed at physiological levels,
and the balance between cell proliferation and apoptosis is preserved. b) In tumour cells, NPM is
often over expressed, and can exert its oncogenic potential both by stimulating cell proliferation
and preventing apoptosis. c) NPM over expression can lead to increased cell growth and
proliferation through hyperactivation of the ribosome machinery, in view of its role as a ribosome
biogenesis factor. NPM, together with a number of ribosomal proteins, is a transcriptional target
of MYC. The altered activity of MYC in tumour cells correlates with increased protein synthesis.
In addition, NPM is a putative stimulatory factor for DNA polymerase-α (DNA Polα), and
contributes to cell-cycle progression. d)Over expressed NPM shows oncogenic potential by
opposing apoptosis through different mechanisms: it prevents the DNA-binding activity of the
transcription factor interferon regulatory factor 1 (IRF1); it binds to and inhibits the catalytic
function of eukaryotic initiation factor 2 kinase PKR; it opposes the DNA-fragmentation activity of
caspase-activated DNAse (CAD) in neural cells, thereby suppressing its pro-apoptotic activity;
and finally, it interacts with and inhibits p53 in response to apoptotic stimuli.
Studies of NPM1 functional domains reveals a nuclear localisation signal (NLS) 
that drives NPM1 from the cytoplasm to the nucleoplasm where it is translocated 
to the nucleolus through its nucleolar-binding domain, particularly tryptophans 
288 and 290 [9]. Nuclear export of NPM1 is mediated by evolutionary conserved 
Exportin 1, the export receptor of proteins containing leucine-rich nuclear export 
signal (NES) motifs with the generally accepted loose consensus L-x(2,3)-
(LIVFM)-x(2,3)-L-x-(LI), a core of closely spaced leucines or other large 
hydrophobic amino acids. Two such highly conserved NES motifs have been 
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identified in the wild type NPM1 protein: one with the sequence I-xx-P-xx-L-x-L 
within residues 94 to 10228 and another at the N-terminus within amino acids 42 
to 61, with leucines 42 and 44 as critical nuclear export residues. However, 
despite the NES motifs, NPM1 remains localised in nucleoli. Thus, in physiologic 
conditions, nuclear import of wild type NPM1 greatly predominates over export, 
since wild type NPM1 NES motifs exhibit the general property of NES motifs (ie, 
weak interaction with Exportin 1) [10]. 
Effects and types of mutations in NPM1 
NPM1 mutations have recently been associated with AML [11]. Mutations of 
NPM1 generate an additional leucine-rich NES motif reinforcing nuclear export 
[12]. They also cause loss of tryptophan residues 288 and 290 (or 290 alone), 
which determine the NLS [4]. Evidence exists that wild type NPM1 is recruited 
by mutated form causing delocalisation into the nucleous and cytoplasm from 
the nucleolus [13]. 
Knockout mice models of NPM1 led to the development of a pre-leukemic 
Myelodysplastic syndrome (MDS) like disease. This may be due to improper 
control of centrosome duplication leading to genomic instability. Although acute 
leukaemia does not develop in these mice, it is thought that secondary 
mutations such as Fms like tyrosine kinase 3  internal tandem duplications 
(FLT3 ITD), which are also commonly associated with AML are the second-hit 
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required for leukemic transformation [7] implying that NPM1 mutation may be a 
primary event in leukaemogenesis. 
However mutated NPM1 remains effective in regulating centrosome duplication 
and NPM1 mutations are extremely rare in humans with MDS [14] therefore 
other mechanisms must be involved. Delocalisation of NPM1 and ARF from 
nucleolus to cytoplasm leading to an unopposed MDM2 degradation of p53 may 
cause cell cycle progression [15]. 
AML is a heterogeneous group of diseases, which relies on cytogenetic analysis 
to subtype and in turn prognosticate. Up to 50% are however normal with 
conventional cytogenetics [16]. With the development of molecular diagnostics 
and the strong association of AML with certain mutations, the World Health 
Organisation (WHO) has recently introduced a new molecular provisional entity 
into the classification of AML called “AML with gene mutations” and includes 
NPM1, as well as CCAT box enhancer binding protein alpha (CEBPA) mutations 
[17].  
NPM1 mutation, if present alone (not associated with Flt3-ITD) is associated 
with significantly better overall survival and disease free survival [18]. 
. 
Mutated NPM1 is also strongly associated with a normal karyotype. In one 
recent study of 1395 patients with AML, 686 had an abnormal karyotype, with 
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only 8% (58/686) of these patients having NPM1 mutations. The remaining 709 
patients with a normal karyotype showed NPM1 mutation rate of 46% (324/709). 
The 8% of patients with NPM1 mutations and abnormal karyotype showed 
mostly single genetic abnormalities like trisomies, monosomies and deletions. 
Only very rarely (<1%) was there an association with t(8;21) and inv(16) [18]. 
This was confirmed in a large study using 1393 patient with AML. 835 showed a 
normal karyotype and 558 abnormal. Of the 558 patients with the abnormal 
karyotype 246 showed reciprocal translocations confirmed by RT-PCR or FISH. 
None of the 246 patients with the reciprocal translocations had NPM1 mutation 
on PCR. Reciprocal translocations included t(8;21), inv(16), t(15;17), 
Chromosome 11q23 rearrangements and t(6;9) [19]. Hence the NPM1 mutated 
state may be used as a predictor that the patient is unlikely to have a reciprocal 
translocation, dispelling the need for expensive tests such as FISH and PCR for 
identifying specific translocation if standard cytogenetics testing fails [19]. 
Six major variants of NPM1 mutations (Types A-F) have been described all 
leading to frame shift mutations [4]. Type A is a duplication of TCTG (956 – 959) 
resulting in a frame shift causing the last 7 amino acids to be replaced with 11 
different ones. [4]. Type A mutations are by far the most common and account 
for 75 – 85% of cases with mutations B and D observed in 10% and 5% 
respectively [10]. Other mutations are very rare [10] (Types B, C and D results in 
a 4bp insertion at position 960 again causing a frame shift mutation, which has a 
similar effect as Type A. Type E and F occur as a result of a 5bp GGAGG (965-
 14 
969) deletion, as well as a 9bp insertion in this position leading to a total gain of 
4bp. All six types amazingly share the same last 5 amino acids in the C-terminal 
VSLRK [4]. Various other mutations have been described, the vast majority 
leading to the common amino acid C-terminal [13]. 
 
Current methodology uses various RT-PCR and genomic DNA PCR techniques 
to detect NPM1 mutations. Although these methods are robust and relatively 
easy to perform they are expensive and labour intensive. Detection methods 
include capillary zone electrophoresis, polyacrylamide gel electrophoresis, 
denaturing high performance liquid chromatography as well as new assays for 
specific mutations (Type A) using fluorescence resonance energy transfer 
(FRET) probes [20-22]. The turnaround time for these assays is also usually 
more than 24 hours. A flow cytometric technique should be simple, cheap and 
done on the same day as the bone marrow giving immediate results and thus 
the ability to decide whether to cancel cytogenetics testing if NPM1 is mutated.  
Flow cytometry will be a novel technique and has never been evaluated for this 
particular purpose. The mutation specific antibody has however been used to 








The research strategy is to compare the new flow cytometry methodology with a 
well-established NPM1 mutation detection technique: PCR - capillary 
electrophoresis. This will involve establishing both methodologies and 
comparing the results obtained from both when used to analyse patients 
simultaneously. 
 
This project will run over 12 to 18 months. The first 6 months will be dedicated to 
setting up the particular tests using flow cytometry and PCR and validating these 
assays with a commercial cell line positive (NPM1 mutant) control. All equipment 
required is available either in the C17 Core Laboratory or C21 molecular 
laboratory. 
 
The antibody will then be used in routine flow cytometry performed on all new 
acute leukaemias (peripheral blood or bone marrow) and information 
accumulated and correlated with PCR results and routine cytogenetics results. 




The study population will consist of all patients of any age group presenting with 
acute leukaemia that would receive routine bone marrow biopsies, 
immunophenotyping by flow cytometry, cytogenetics and routine molecular 
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investigations. The project will be reviewed by the local ethics committee and 
approval obtained. Written informed consent (see attached consent form) will be 




The cell line OCI-AML3 obtained from the German Collection of microogansims 
and cell cultures (GCMZ) will be cultured in alpha-minimal essential medium 
(Invitrogen) combined with 20% fetal bovine serum (Gibco). These cells contain 
the following mutation: Type A NPM1 and will be used as a positive control for 
the establishment of the PCR and flow detection methods.d 
 
For PCRe analysis of NPM1, DNA will be extracted from the tissue culture using 
standard spin column extraction procedures (Invivoscribe). PCR will be 
established using the protocol described by Szankasi and co-workers [23]. 
Briefly, the following NPM1 primers (0.2 µmol/L): NPM-F, 6-FAM-
5’GATGTCTATGAAGTGTTGTGGTTCC-3’ and NPM-R,5’ 
GGACAGCCAGATATCAACTG-3’ will be used in a 20µl PCR reaction 
containing 100 ng of genomic DNA,, deoxynucleoside-5’-triphosphates (0.2 
mmol/L each), 1X cloned Pfu buffer (Stratagene), 1.25units of Pfu Turbo 
(Stratagene), MgCl2 (3.5 mmol/L final), where 1.5 mmol/L MgCl2 is contributed 
                                                
dDue to difficulty in importing the cell line from Germany and this company 
directly, a group in the United States of America donated the cells. 
eUltimately a different DNA based PCR methodology was used, as this method 
did not give clear results – see Part 3 of the dissertation 
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by the cloned Pfu buffer. PCR program as follows: initial denaturation at 94°C for 
2 minutes, 35 cycles of 94°C for 20 seconds, 60°C for 20 seconds, 72°C for 20 
seconds, followed by a hold at 72°C for 2 minutes. The 6-FAM labeled PCR 
products will be diluted fivefold in water, and 1µl mixed with 9 µl of HiDi 
formamide (Applied Biosystems).  GeneScan ROX 350 internal size standards 
(Applied Biosystems) will be added (0.5µl) and the samples heated to 95°C for 2 
minutes. The samples will be run on an ABI 3130xl Genetic Analyzer using 36-
cm capillaries and POP-7 polymer. The samples will be injected at 2 kV for 5 
seconds and run at 15 kV for 950 seconds at 60°C. Raw data will be analysed 
with GeneMapper v4.0 software (Applied Biosystems, Inc.)  
 
A new method using flow cytometry and NPM1 mutation specific antibody 
(ABCAM) will be developed. The antibody is polyclonal and of rabbit origin but is 
not conjugated. A FITC conjugation kit will be used for conjugation purposes. 
Cells will be permeabilised using FACS PERM (Becton-Dickinson) and labeled 
with the antibody using standard intracellular staining protocols. Optimum 
antibody concentrations as well as staining methodology will have to be 





                                                
fFACS Calibur was replaced with a FACS Canto II during the study period 
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Envisaged outputs/outcomes 
It is envisaged that this study will provide a novel, rapid and cost-effective 
method for evaluating the NPM1 mutation status of a patient with AML. The 
application may be used in smaller laboratories without molecular facilities. This 
has prognostic implications in cytogenetically normal AML patients. 
Impact 
Capacity development: 
Training of research workers: 
Dr Du Pisani will be the project leader. He is currently training as a Registrar in 
Haematology and is registered for the MMed Degree at UCT. The project will 
provide training in flow cytometry and molecular techniques and will be the basis 
for the dissertation towards the MMed degree. 
Institutional approval 
This proposal will be submitted for ethics approval to the University of Cape 
Town Research Ethics Committee. 
 19 
Budget 









rabbit antibody  



















































 TOTAL 90000 
 
Funding 
The NHLS Research Trust Fund, subject to ethics approval, will provide funding. 
No other funding has been approved for this project. 
 
Previous NHLS research trust funding 





(1) Okuwaki M. The structure and functions R of NPM1/Nucleophsmin/B23, a
multifunctional nucleolar acidic protein. J Biochem 2008 Apr;143(4):441-448. 
(2) Szebeni A, Olson MO. Nucleolar protein B23 has molecular chaperone
activities. Protein Sci 1999 Apr;8(4):905-912. 
(3) Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins
shuttle between nucleus and cytoplasm. Cell 1989 Feb 10;56(3):379-390. 
(4) Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al.
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal 
karyotype. N Engl J Med 2005 Jan 20;352(3):254-266. 
(5) Bothner B, Lewis WS, DiGiammarino EL, Weber JD, Bothner SJ, Kriwacki
RW. Defining the molecular basis of Arf and Hdm2 interactions. J Mol Biol 2001 
Nov 23;314(2):263-277. 
(6) Kuo ML, den Besten W, Bertwistle D, Roussel MF, Sherr CJ. N-terminal
polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev 
2004 Aug 1;18(15):1862-1874. 
(7) Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K, et al.
Role of nucleophosmin in embryonic development and tumorigenesis. Nature 
2005 Sep 1;437(7055):147-153. 
(8) Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer.
Nat Rev Cancer 2006 Jul;6(7):493-505. 
21 
(9) Nishimura Y, Ohkubo T, Furuichi Y, Umekawa H. Tryptophans 286 and 288
in the C-terminal region of protein B23.1 are important for its nucleolar 
localization. Biosci Biotechnol Biochem 2002 Oct;66(10):2239-2242. 
(10) Falini B, Albiero E, Bolli N, De Marco MF, Madeo D, Martelli M, et al.
Aberrant cytoplasmic expression of C-terminal-truncated NPM leukaemic mutant 
is dictated by tryptophans loss and a new NES motif. Leukemia 2007 
Sep;21(9):2052-4; author reply 2054; discussion 2055-6. 
(11) Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of
the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 2004 
Feb;24(3):985-996. 
(12) Nakagawa M, Kameoka Y, Suzuki R. Nucleophosmin in acute myelogenous
leukemia. N Engl J Med 2005 Apr 28;352(17):1819-20; author reply 1819-20. 
(13) Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A, et al. Both
carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant 
nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 2006 
Jun 1;107(11):4514-4523. 
(14) Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia
carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and 
clinical features. Blood 2007 Feb 1;109(3):874-885. 
(15) Colombo E, Martinelli P, Zamponi R, Shing DC, Bonetti P, Luzi L, et al.
Delocalization and destabilization of the Arf tumor suppressor by the leukemia-
associated NPM mutant. Cancer Res 2006 Mar 15;66(6):3044-3050. 
 22 
(16) Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. 
The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 
patients entered into the MRC AML 10 trial. The Medical Research Council Adult 
and Children's Leukaemia Working Parties. Blood 1998 Oct 1;92(7):2322-2333. 
(17) Swerdlow H, Campo E, Harris N, et al editors. WHO Classification of 
Tumours of Haemopoietic and Lymphoid Tissue. 4th Edition ed. Switzerland: 
WHO Press; 2008. 
(18) Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, et al. 
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients 
with acute myeloid leukemia (AML). Blood 2006 May 15;107(10):4011-4020. 
(19) Falini B, Mecucci C, Saglio G, Lo Coco F, Diverio D, Brown P, et al. NPM1 
mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent 
genetic abnormalities: a comparative analysis of 2562 patients with acute 
myeloid leukemia. Haematologica 2008 Mar;93(3):439-442. 
(20) Ammatuna E, Noguera NI, Zangrilli D, Curzi P, Panetta P, Bencivenga P, et 
al. Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid 
leukemia by denaturing HPLC. Clin Chem 2005 Nov;51(11):2165-2167. 
(21) Calvo KL, Ojeda MJ, Ammatuna E, Lavorgna S, Ottone T, Targovnik HM, et 
al. Detection of the nucleophosmin gene mutations in acute myelogenous 
leukemia through RT-PCR and polyacrylamide gel electrophoresis. Eur J 
Haematol 2009 Jan;82(1):69-72. 
 23 
(22) Scholl S, Mugge LO, Landt O, Loncarevic IF, Kunert C, Clement JH, et al. 
Rapid screening and sensitive detection of NPM1 (nucleophosmin) exon 12 
mutations in acute myeloid leukaemia. Leuk Res 2007 Sep;31(9):1205-1211. 
(23) Szankasi P, Jama M, Bahler DW. A new DNA-based test for detection of 

























PART B: LITERATURE REVIEW 
The development of a flow cytometric method to detect the presence of 
mutated nucleophosmin in Acute Myeloid Leukaemia 
Objectives 
Review literature pertaining to Nucleophosmin deletion/insertion mutations and 
their role in Acute Myeloid Leukaemia pathogenesis including: 
1. Normal physiological function
2. Types of mutations and their effects
3. Methods of detection
4. Utilising NPM1 mutation detection in Minimal Residual Disease
monitoring
5. Conclusions and further areas of study
Literature search strategy 
Pubmed was used as the primary search engine. Articles in languages other 
than English and those not available via the University of Cape Town were 
excluded. Referencing was performed using RefWorks 
Search parameters included: 
1. Nucleophosmin
2. NPM1
3. Nucleophosmin 1 deletion/insertion mutations
4. Acute myeloid leukemia/leukaemia
5. AML
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Summary of literature 
Nucleophosmin 1 (NPM1) – structure and normal physiologic functions 
Nucleophosmin (occasionally referred to as B23 [1], NO38 [2] or numatrin [3]) is 
an acidic nucleolar phosphoprotein with a predominant nucleo-cytoplasmic 
shuttling function [4]. The protein is encoded by the NPM1 gene located on 
chromosome 5q35. It consists of 12 exons spanning a 30kb region (OMIM / 
NCBI data base) and 3 mRNA splice variants can be produced, although only 
one protein isoform dominates in the cell, the 37kDa protein referred to as 
NPM1 [5,6]. This protein is present predominantly in the nucleolus, but can 
shuttle between the nucleus and the cytoplasm [7,8]. This shuttling is extremely 
important in maintaining cellular processes and changes in this function have 
clinical implications and will be discussed later in this review [9].  
 
A study of NPM1 functional domains revealed a nuclear localisation signal 
(NLS), nucleolar localisation motif (NoLS) (including two essential tryptophan 
amino acids at position 288 and 290), and 3 nuclear export signals (NES) (see 
fig. 1). These motifs allow movement of NPM1 between the cytoplasm, 
nucleoplasm and nucleolus of the cell [10]. Exportin 1 is a nuclear export factor, 
which binds to proteins containing leucine-rich NES motifs, such as NPM1 and 
mediates nuclear export of these proteins back into the cytoplasm. Despite the 
NES motifs however, NPM1 remains largely localised in the nucleolus under 
normal physiological conditions. This is due to the weak interaction of the wild 
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type NPM1 NES motifs with Exportin1, which leads to nuclear import of wild type 
NPM1 predominating over export [11].  
Figure 1: Basic functional domains of NPM1 protein (adapted from Falini et al., 2007) [11] 
Nuclear export signal (NES) motifs and a metal-binding (MB) domain shown at the N-terminal. 
Nuclear localisation signal (NLS) and acid stretches (AC) for histone binding present in the 
middle. C-terminus with ribonuclease activity and involved in nucleic-acid binding. NPM1 
specifically contains two very important tryptophan residues (288 and 290), required for 
nucleolar localisation of the protein (NoLS). Numbers refer to different exons. 
NPM1 has multiple functions in the cell, some of which can be regarded as 
promoting proliferation and are anti-apoptotic, while others are tumour 
suppressive, participating in pathways that control the cell cycle and promote 
apoptosis. These specific functions are dependent upon the localisation of the 
protein, which is achieved due to its shuttling capabilities (as described earlier). 
NPM1 can also act as a molecular chaperone, helping to transport other 
proteins or molecules across the nuclear membrane. Fig. 2 highlights some of 
the major functions of NPM1 in the various cellular components. 
NPM1 is present predominantly in the nucleus and thus the majority of its 
functions take place here. This largely entails cell cycle regulation and other 
processes involved in cellular proliferation. Nucleoplasmic NPM1 regulates the 
p14-Alternate reading frame (ARF) / p53 pathway by promoting nucleolar 
localisation and stability of ARF, which is in turn involved in cell-cycle control 
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(see fig. 2) [9]. During oncogenic stress, NPM1 expression is upregulated, thus 
causing accumulation and stabilisation of ARF in the nucleus. The function of 
ARF is to stabilise Murine Double Minute 2 (MDM2) protein and prevent its 
attachment to and destruction of p53 [12,13]. Overall, this leads to increased 
p53 and cell cycle arrest. Loss of NPM1 expression or functional changes of the 
protein due to mutation will abrogate this effect and may contribute to 
tumourigenesis [14]. 
Other nuclear functions include involvement with DNA repair mechanisms, as 
NPM1 is markedly upregulated after UV radiation [15] and shows 
chromatin/histone binding functions when DNA double-stranded breaks are 
present utilising the acid stretch regions (see fig. 1) [16]. NPM1 also initiates 
centrosome duplication, the formation of two daughter centrosomes just before 
cellular mitosis, by acting as a substrate for cyclin dependant kinase 2/cyclin E 
and thus assists in this process [17]. NPM1 seems to protect the cell from 
centrosome hyperamplification and allows the cell to progress from G2 to M 





Figure 2: Basic functions of NPM1(adapted from Falini et al., 2007)[21] 
NPM1 moves between the nucleus and cytoplasm. Shuttling itself is important for ribosome 
biogenesis via transport of pre-ribosomal particles. In the cytoplasm, NPM1 binds to the 
centrosome - this regulates its duplication during cell mitosis. NPM1 also interacts with and 
regulates ARF-p53-HDM2 pathway in the cell cycle  
 
Although predominantly in the nucleus, NPM1 has one cytoplasmic function. It 
interacts with Breast Cancer Type 1 (BRACA1) protein and BRACA-associated 
RING domain 1 (BARD1). The NPM1 and BRCA1-BARD1 complex localises at 
the centrosomes, which seems important for maintaining the mitotic spindle 
poles, genomic stability and integrity during mitosis [17]. 
 
NPM1 also has molecular chaperone functions by virtue of its ability to shuttle 











to assist in de novo protein folding, stabilisation of proteins under stress 
conditions and maintaining polypeptide chain components in a loosely folded 
state for translocation across organellar membranes [22]. As a molecular 
chaperone, NPM1 is involved in ribosome biosynthesis. Ribosomes play a 
central role in protein synthesis, growth and development.  NPM1 regulates the 
assembly and transport of pre-ribosomal particles across the nuclear 
membrane, via its nucleo-cytoplasmic shuttling and ability to bind nucleic acids 
[7,23,24] thus playing a role in ribosomal biogenesis. NPM1 also expresses 
ribonuclease activity and can process pre-ribosomal ribonucleic acid molecules 
[25,26]. NPM1 also acts as a molecular chaperone for GADD45, as it lacks its 
own intrinsic NLS [27]. GADD45α is a protein induced by genotoxic stress, with 
its primary roles including DNA repair and cell cycle arrest [28] via the p53 
pathway. 
 
Types of NPM1 mutations and their effects 
Deletion/Insertion mutations in exon 12 of NPM1 gene (NPM1 DIM) are 
commonly seen in Acute Myeloid Leukemia (AML). These mutations result in the 
loss of the two fundamentally important tryptophan residues within the NoLS and 
the creation of an extra NES motif, which subsequently disrupts the shuttling 
function and protein localisation. Rare cases of mutations within other exons 
have also been reported [29-31]. 
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Six major variants of NPM1 DIM (Types A-F) have been described, all of which 
lead to frame shift mutations [9]. Type A is a duplication of TCTG at nucleotide 
956 – 959. This effectively leads to a frame shift, which causes the last seven 
amino acids to be exchanged with eleven different ones [9]. Types B, C and D 
results in a four base pair (bp) insertion at nucleotide position 960, again 
causing a frame shift mutation, which has a similar effect to the type A insertion. 
Type E and F occur as a result of a five bp GGAGG (nucleotide 965-969) 
deletion, as well as a nine bp insertion in this position leading to a total gain of 
four bp. All six major mutation types result in the same last five amino acids in 
the C-terminal: VSLRK [9]. Type A mutations are by far the most common and 
account for 75 – 85% of cases with mutations B and D observed in 10% and 5% 
respectively [11]. Other mutations are very rare [11]. 
 
Despite the various combinations of deletions and insertions that may occur in 
exon 12, the alteration of the last five amino acids in these mutants results in an 
additional leucine-rich NES motif, which favours export from the nucleus to the 
cytoplasm [32,33]. It is important to note that it also causes the loss of 
tryptophan residues 288 and/or 290, which forms part of the NoLS [9]. 
Essentially these mutations change NPM1 from a protein that is preferentially 
imported into the nucleus and the nucleolus, to one that is predominantly 
exported to the cytoplasm. As described above, this will seriously change the 
predominant role that NPM1 plays in the cell, abrogating nuclear functions. 
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To further compound the effects of the mutations on cellular function, there is 
evidence that wild type NPM1 protein is recruited by the mutated isoform to 
create heterodimers, which results in the delocalisation of the remaining wild 
type protein into the cytoplasm [34]. This essentially causes a dominant negative 
effect when a heterozygous mutation is present and negates the effect of the 
normal remaining NPM1 chaperone functions 
 
In conclusion, NPM1 plays an important role in regulation of the cell cycle via its 
interaction with ARF-p53 pathway. Displacing it into the cytoplasm due to the 
mutation may result in the loss of this function, resulting in down regulation of 
p53, cell cycle progression and prevention of apoptosis. Disruption of the 
shuttling of NPM1 and thus its ability to act as a chaperone will also result in 
ribosomal biogenesis failure, which will have an impact on growth, development 
and differentiation of cells.  
 
Characteristics of AML with NPM1 DIM: effecton prognosis and treatment  
AML is a neoplasm of a specific lineage of blood cells, characterised by the 
rapid proliferation and accumulation of immature myeloid precursor cells in the 
bone marrow, with disruption of the normal blood cell production [35]. 
 
AML actually encompasses a heterogeneous group of diseases, which 
traditionally relied on morphology, cytochemistry and cytogenetic analysis to 
subtype and in turn prognosticate [35] (review). In those AML subtypes with 
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recurrent cytogenetic abnormalities, three broad prognostic categories were 
established [36] (review): 
a) Favourable, consisting of the core binding factor leukaemias - t(8;21),
inv(16)
b) Intermediate, consisting of t(9;11)
c) Poor, associated with inv(3), t(3;3), t(6;9), other 11q23 rearrangements,
complex karyotypes, -5, del(5q), -7 or abln(17p)
Up to 50% of AML’s however demonstrate a normal cytogenetic profile with 
conventional cytogenetics (CN-AML), [37] and as a consequence, a new 
category named “AML with gene mutations” was introduced by the World Health 
Organisation (WHO) in 2008, to try to sub-categorise these patients and aid with 
therapy decisions. AML cases in this category have normal cytogenetic profiles 
and at least one of the mutations listed by the WHO, which includes mutations in 
Fms-like tyrosine kinase 3 (FLT3), NPM1 and CAT box enhancer binding protein 
alpha (CEBPA). The prognosis of cases within these “molecular” groups differs 
and is dependent upon the mutation type found. CEBPA mutations, NPM1 DIM 
and FLT3 internal tandem duplications (ITD) seem to have the highest 
prognostic value [38]. Generally NPM1 DIM [30] and CEBPA mutations [39] are 
considered to convey a good prognosis and FLT3-ITD [40] a poor prognosis. 
The combination of mutations also alters the prognostic value of the individual 
mutations, with co-existence of FLT3-ITD negating the positive prognostic effect 
of NPM1 DIM [41].  
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A large number of CN-AML cases have NPM1 DIM and the opposite is true as 
well – NPM1 DIM is strongly associated with a normal karyotype in AML. Only a 
small minority of patients with NPM1 DIM mutations have single genetic 
abnormalities like trisomies, monosomies and deletions [30] and this has been 
confirmed in several large studies [42,43]. No AML, with a WHO recognised 
recurrent cytogenetic abnormality, was detected in the group of AML cases with 
NPM1 DIM [42,43]. Hence the NPM1 mutated state may be used as a predictor 
that the patient is unlikely to have a reciprocal translocation, dispelling the need 
for expensive tests such as FISH and PCR for identifying specific translocation if 
standard cytogenetics testing fails [42].  
 
NPM1 DIM are overall more common in females with a median age of 46 years 
and are associated with some degree of monocytic differentiation in AML, as 
well as lower expression of CD34 [44-46].  
 
Patients with AML NPM1 DIM alone generally show an improved prognosis in 
relation to other AMLs (as discussed previously). CN-AML with NPM1 DIM show 
high blast counts [47] and dysplasia [48]. These characteristics have classically 
been interpreted as poor prognostic indicators [49], however they do not seem 
to apply in this setting showing the importance of establishing the status of this 
mutation. The mechanism by whichNPM1 DIM, when present without FLT3- 
ITD, convey a better prognosis is not well understood [50]. 
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CN-AML is a very heterogeneous group of AML’s in which only high-risk groups 
benefit from an allogeneic stem cell transplant as this type of treatment carries 
an inherent risk of mortality. Here the mutation status of the patient plays an 
important role in determining therapy.  Patients younger than 60 years with CN-
AML, wild type NPM1 and wild type CEBPA, but mutated FLT3 (FLT3-ITD) 
should be considered for allogeneic stem cell transplant [38] as the risk of 
relapse outweighs the risk of mortality and morbidity associated with the 
transplant. NPM1 DIM or CEBPA mutations, without FLT3-ITD however is 
associated with significantly better overall survival and disease free survival [30] 
and allogeneic stem cell transplant does not result in improved survival 
compared to post remission consolidation with chemotherapy [46]. Patients 
older than 60 years with CN-AML show similar improvement in prognosis when 
associated with NPM1 DIM alone. These AML cases also expressed a similar 
microRNA and gene expression profiles compared to younger patients with 
NPM1 DIM [51] and this is likely the same disease. Elderly patients who are 
medically fit and have CN-AML with no FLT3-ITD or NPM1 DIM only, should be 
considered for post remission therapy (e.g. Allogeneic stem cell transplant) [52].  
 
The mutated NPM1 protein itself may in future be useful as a treatment target. 
NPM1 DIM is stable throughout the disease, probably a founder 
mutation/primary genetic event and is restricted to the leukaemic cells [53]. All 
TransRetinoicAcid (ATRA) administration after completion of three days of 
induction chemotherapy has been used in elderly patients with CN-AML with 
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NPM1 DIM and these patients showed an improved outcome compared to those 
than received standard chemotherapy alone [54]. This result may be due to the 
enhanced cytoplasmic NPM1 function as a possible co-repressor during retinoic 
acid-induced cell differentiation, when this protein is mutated. Studies supporting 
this hypothesis showed that ATRA, in pharmacological doses, induced cell cycle 
arrest and apoptosis in OCI/AML3 a NPM1 mutated cell line [54]. Demethylating 
(5-azacytidine) agents have also recently been successfully used to suppress 
NPM1 levels at relapse [55], the mechanism of which is largely unknown.  
Detecting NPM1 DIM in AML 
Polymerase chain reaction (PCR) 
Various RNA-based reverse transcriptase PCR (RT-PCR) and genomic DNA 
based PCR techniques to detect NPM1 DIM are currently being reported in the 
literature. Detection methods include direct sequencing [9], capillary 
electrophoresis [56], polyacrylamide gel electrophoresis [57], denaturing high 
performance liquid chromatography [58] as well as new assays for specific 
mutations (Type A) using fluorescence resonance energy transfer (FRET) 
probes and real-time PCR approaches [59,60]. Although these methods are 
robust and relatively easy to perform, they can be expensive and labour 
intensive depending upon the methodology employed. Sensitivity of assays 
ranges from 20% with direct Sanger sequencing [9] to 0.0001% with semi-
nested allele specific oligonucleotide RT-PCR techniques [58]. The more 
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sensitive assays allow for the monitoring of minimal residual disease (discussed 
below) [58,61,62].  
 
Antibody mediated protein detection 
As an alternative approach, the detection of the abnormal protein product can 
either be achieved by detecting it in an abnormal location (the cytoplasm) or by 
detecting the specific change in amino acid structure due to the mutation. 
 
Immunohistochemistry (IHC) 
As previously mentioned, mutated NPM1 protein localisation is skewed towards 
that of the cytoplasm. The mutated protein, due to dimerisation, also causes the 
wild type NPM1 to be predominantly present in the cytoplasm. This provides the 
opportunity to use this physical property for diagnostic purposes. IHC, using an 
antibody that detects both WT and mutated NPM1 has previously been used on 
bone marrow trephines to detect the abnormal cytoplasmic localisation of NPM1 
and thus predict if NPM1 is mutated or not [74]. Reliable and consistent results 
could not however be obtained when using smears and cytospin preparations 
[63]. One study [64] disputed the accuracy of the IHC results even on the bone 
marrow trephines, showing some discordance between cytoplasmic localisation 
of NPM1 detected with IHC compared to mutation screening by PCR, 
concluding that PCR cannot be replaced by IHC. This may be due to NPM1 
diffusion during tissue fixation and the use of different fixatives influencing the 
IHC technique [64]. 
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Flow cytometry 
Recently an Italian group [63] developed an unconjugated NPM1 monoclonal 
antibody (mAb) called T26. As previously mentioned, NPM1 mutated proteins 
have a novel C-terminal sequence of eleven amino acids, with the last five 
(VLSRK) being common to all currently described mutants [9]. In this study, a 
19-amino acid C-terminal peptide was used to generate the mAb containing
eight amino acids from WT NPM1and the last five commonly shared amino 
acids from the mutated NPM1 (CQEAIQDLCLAVEE-VLSRK) [9,63]. To confirm 
that the mAb specificity was restricted to the NPM1 mutated sequence, a study 
correlating NPM1 DIM detection via PCR with flow cytometry, using cells from 
39 de Novo AML patients was performed - 24 tested negative and 15 positive on 
flow cytometry with perfect concordance with PCR. The range of NPM1 DIM 
mutation types was however limited in this study, with 93% of the positive 
patients showing the type A mutation. Sensitivity of detection using this antibody 
was evaluated by performing serial dilutions using a positive NPM1 DIM cell line 
(OCI/AML3) and a promyelocytic leukaemia cell line with wild type NPM1 (HL-
60). Detection of the positive cells was possible even as low as 0.001%. 
However, this could be criticised as performing dilutions with a single negative 
cell line may not truly be representative of flow cytometry on a bone marrow or 
peripheral blood sample. In these scenarios many more populations of different 
cell types may be present; some overlapping with commonly used gating 
strategies. Tan et al (2011) attempted a similar study and developed their own 
antibody (2G3), but showed significant cross reaction with the wild type NPM1 
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[65], bringing into question the usefulness and robustness of antibody-based 
techniques. Imaging flow cytometry to assess the localisation of NPM1 in the 
cell after using an antibody for NPM1 protein, have also been successfully 
performed, this technology is unfortunately not commonly available at the 
moment [75].Flow cytometry is however relatively easy to perform, provides 
same day results and may be applicable to settings where molecular testing 
laboratories and equipment is not available. This technique thus requires further 
study. 
 
Minimal residual disease (MRD) monitoring in CN-AML by monitoring NPM1 
DIM 
AML patients with recognised cytogenetic abnormalities such as translocations 
are relatively easy to monitor either by FISH or by RNA-based transcript 
monitoring. However, due to the lack of these hallmark genetic rearrangements, 
most CN-AML cases are not amendable to the same techniques. Phenotypic 
shifts and lack of aberrant markers may also hamper MRD monitoring by flow 
cytometry. 
 
In the subgroup of “AML with gene mutations”, several of these smaller 
mutations have been investigated as MRD markers. NPM1 DIM was found to be 
more consistently present at relapse than FLT3-ITD and thus represented a 
more stable marker for monitoring residual disease in AML than FLT3 mutations 
[66]. However not all studies have demonstrated this stability and loss of NPM1 
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DIM in up to 9% of patients has been reported during the evolution of the 
disease [67,68]. Caution is thus required when using this mutation as an MRD 
marker. 
 
A number of studies which looked at large patient groups with NPM1 DIM [68-
70] showed that clinical and morphological relapses could be predicted several 
weeks earlier by monitoring NPM1 levels using sensitive mutation–specific real-
time quantitative polymerase chain reaction (QRTPCR). Schnittger et al (2009) 
also reported that the NPM1 mRNA level at various time points was predictive of 
event free survival for patients receiving first line therapy, second line therapy 
and allogeneic stem cell transplant for AML [68]. 
 
One study focusing specifically on overall survival (OS) and remission duration, 
evaluated 245 patients with NPM1 DIM. NPM1DIM mRNA transcript levels were 
measured at multiple time points during therapy and found that at all time points, 
patients with higher NPM1 DIM transcript levels were associated with higher 
relapse rates and shorter survival. The most significant predictive time points 
were after the second induction and at completion with a level of >200 NPM1 
DIM transcripts/104 ABL predictive of relapse [69]. Another study showed that 
failure to obtain at least a two log reduction in NPM1 DIM transcript levels after 




Normal immunophenotyping can be used for monitoring residual disease in AML 
[72] however this can at times be taxing. Incorporating NPM1 mutation flow 
cytometry may assist in performing these flow cytometry MRD assays when the 
mutation is present. The assay and antibody developed for detecting mutated 
NPM1 by Gruszka et al (2010) researched sensitivity levels of 0.001%, 
appropriate for these applications [63]. Flow cytometry results may be available 
quicker than QRTPCR, assisting in making immediate management decisions.  
 
Conclusion and identification of needs for further research 
NPM1 is a nucleo-cytoplasmic shuttling protein with numerous functions relating 
to cellular proliferation. The protein is predominately located in the nuclear 
compartment and has a sophisticated structure controlling the movement 
through the nucleosome and cytoplasm to fulfill its various functions. When the 
balance between nuclear import and cytoplasmic export is disturbed (as in the 
case of mutations), this can lead to the disruption of normal NPM1 functions, 
causing dysregulation of a number of cellular functions involved with cell cycle 
regulation and ribosomal protein assembly.  
 
NPM1 DIM have been found in CN-AML and have been shown to be associated 
with a better prognosis when occurring in isolation. The presence of these 
mutations not only serves as a prognostic tool and guide for treatment, it also 
serves to eliminate unnecessary expensive additional testing (i.e.: FISH and 
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cytogenetics), as it is mutually exclusive from the AML-associated 
translocations. Only FLT3-ITD testing is additionally required. 
A number of methods are available to detect these mutations including PCR 
based assays and detecting the mutated protein directly or its abnormal position 
within the cell, using immunohistochemistry or flow cytometry. Antibodies 
developed against specific mutated proteins provide the unique opportunity to 
detect genetic mutations at the translational level. Using antibodies on a flow 
cytometry platform provides the added benefit that it is fast and relatively easy to 
use. As all of the relevant exon 12 mutations for NPM1 result in the alteration of 
the last five amino acids, theoretically a single antibody can be used to detect all 
the variants. Although a few groups have developed their own monoclonal 
antibodies against the mutated protein, their results on the efficiency and 
specificity of the assays are contradictory and more work is needed to establish 
if this technology is applicable. Unfortunately monoclonal antibodies developed 
by these groups are not yet commercially available, making it difficult to evaluate 
these studies directly. A mutation specific unconjugated polyclonal antibody for 
NPM1 is however commercially available and this provides the opportunity for 
future study and development of a technique that can be implemented by any 
laboratory with expertise and availability of a flow cytometer. 
Although PCR-based assays are currently used more often, the use of a flow 
cytometric methodology at diagnosis, when flow cytometry panels are routinely 
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used to characterise the leukemia, would not only be cost-effective and more 
rapid (than PCR), but also a more efficient use of labour. Additionally it may 
negate the need for expensive cytogenetics and FISH analysis in the situation 
that the NPM1 mutation is present as virtually all AML patients, that prove to 
have this mutation, have normal cytogenetics. Many smaller laboratories may 
have access to flow cytometry but do not have extensive molecular facilities or 
expertise in this field. The development of bead-based assays to detect 
chromosomal translocations in Haematology, using flow cytometry, echoes this 
sentiment [73]. Therefore the development of a reliable flow cytometry assay will 
make the detection of these mutations more accessible. 
The aim of this study was therefore to develop a robust flow cytometry 
methodology that could be used in the routine assessment of AML samples to 
determine the mutational state of NPM, using a commercially available 
polyclonal antibody against the mutated NPM1. To achieve this aim, the study 
was composed of several objectives, including the determination of the optimal 
concentration of both primary and secondary antibodies and finalising a 
protocol; characterising the assay performance in terms of sensitivity, 
repeatability and robustness and finally evaluating the assay using patient 
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Abstract 
The development of a flow cytometric method to detect the presence of 
mutated nucleophosmin in Acute Myeloid Leukaemia 
LA Du Pisani; K Shires – National Health Laboratory Service – Groote Schuur 
and the University of Cape Town 
Introduction: 
NPM1 is a protein that plays multiple roles in cell growth and proliferation. 
Deletion insertion mutations of NPM1 seem to disrupt it normal physiologic role 
as a molecular chaperone. NPM1, if present alone (not associated with Flt3-ITD) 
however, is associated with significantly better overall. The aim of this study was 
to develop a flow cytometry methodology to detect NPM1 DIM. 
Methods: 
NPM1 mutation specific antibody was used to develop a diagnostic method by 
flow cytometry. Optimal antibody concentration, blocking technique for non-
specific binding as well as intracellular staining methodology was established. 
Samples from twelve newly diagnosed AML patients were used to correlate the 
NPM1 flow cytometry assay with DNA based PCR. Median Fluorescence 
Intensity ratio (patient :negative control) of greater than 1.8 was established to 
optimally differentiate positive and negative patients on flow cytometry. 
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Results: 
Flow cytometry was able to detect NPM1 DIM positive blast populations of just 
less than 10% on dilution studies. Two of the twelve patients were positive for 
NPM1 on both flow and PCR and ten were negative.  
 
Conclusions: 
Flow cytometry may be utilised as a relatively cost effective, rapid alternative to 


















Acute Myeloid Leukaemia (AML) is a neoplasm of a specific lineage of blood 
cells, characterised by the rapid proliferation and accumulation of immature 
myeloid precursor cells in the bone marrow, with disruption of the normal blood 
cell production [1]. 
 
AML actually encompasses a heterogeneous group of diseases, which 
traditionally relied on morphology, cytochemistry and cytogenetic analysis to 
subtype and in turn prognosticate [1]. In those AML subtypes with recurrent 
cytogenetic abnormalities, three broad prognostic categories were established 
[2] (review): A) Favourable, consisting of the core binding factor leukaemias - 
t(8;21), inv(16),  B) Intermediate, consisting of t(9;11) and C) Poor, associated 
with inv(3), t(3;3), t(6;9), other 11q23 rearrangements, complex karyotypes, -5, 
del(5q), -7 or abln(17p). Generally patients in poor prognostic categories would 
be considered for allogeneic stem cell transplant while the others may not [3]. 
Up to 50% of AML patients however demonstrate a normal cytogenetic profile 
with conventional cytogenetics [4], making it difficult to assign these patients to 
any prognostic category.  
 
As a consequence, the World Health Organisation (WHO) introduced a new 
category named “AML with gene mutations” in 2008, which is further divided into 
prognostic groups depending upon the specific gene mutations or combinations 
of mutations [1]. Mutations listed by the WHO in this category include mutations 
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in Fms-like tyrosine kinase 3 (FLT3), Nucleophosmin 1 (NPM1) and CAT box 
enhancer binding protein alpha (CEBPA), which carry a high prognostic value[5]. 
Generally NPM1 deletion/insertion mutations (NPM1 DIM) [6] and CEBPA point 
mutations [7] are considered to convey a good prognosis, while FLT3 internal 
tandem duplications (FLT3-ITD) a poor prognosis [8]. The combination of 
mutations also alters the prognostic value of the individual mutations, with co-
existence of FLT3-ITD negating the positive prognostic effect of NPM1 DIM [9]. 
It is thus of great importance to be able to rapidly identify these mutations before 
treatment protocols are initiated. 
In cytogenetically normal AML (CN-AML), the most common NPM1 mutations 
involve deletions or insertions in exon 12 (NPM1 DIM), with six major variants 
being described (A-F) [10]. All of these NPM1 mutations cause similar changes 
to the last five amino acids at the C-terminus of the protein. This results in 
changes in its nuclear localisation signal [11] and a shift in the balance of 
nuclear export leading to the accumulation of NPM1 in the cytoplasm [10,12,13]. 
This nucleo-cytoplasmic shuttling protein plays an important role in regulation of 
ribosomal biogenesis, as well as cell cycle regulation during oncogenic stress, 
[12,14,15], centrosome duplication and regulation of apoptosis [16]. Its ability to 
shuttle between the nucleolus, nucleus and cytoplasm is paramount to these 
functions, which are then severely inhibited by the NPM1 mutations [10]. 
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While NPM1 DIM are currently detected via PCR techniques, a single C-
terminus, mutation specific antibody could potentially be used for detecting the 
majority of NPM1 DIM subtypes (A-F) and be combined with flow cytometry to 
provide a relatively quick, simple and cost effective method for detecting these 
mutations in newly diagnosed AML patients. It could also be potentially included 
in the immunophenotyping diagnostic panel with minimal additional effort. 
 
Monoclonal antibodies, raised and selected specifically to detect this mutant 
protein, have been developed by two groups [17,18], however discrepant results 
were obtained and these antibodies are not available commercially. One 
polyclonal antibody to detect mutated NPM1 protein is available from a 
commercial company (ABCAM) and has previously been validated in Western 
blotting techniques but has not been extensively studied in the application of 
flow cytometry (personal communication with ABCAM).  
 
The aim of this study was to develop a flowcytometric method to detect mutated 
NPM1 protein in AML patients. The assay development, testing sensitivity, 
repeatability and specificity were assessed using a combination of cell lines and 
clinical samples; in conjunction with NPM1 DIM PCR assessment. The assay 
was also assessed from a cost perspective to evaluate its use in a diagnostic 




Methods and materials 
Cell lines and clinical samples 
The OCI/AML3 cell line, which harbors a confirmed Type A exon 12 DIM 
mutation ofNPM1[19] was used as a positive control in the development of the 
flow cytometry assay (kindly donated by Dr P Szankasi (University of Utah, Salt 
Lake City, Utah, USA)). Cells were cultured in suspension using αMEM (Gibco) 
and 20% FBS (Gibco). A Jurkat T lymphoblastic cell line (ATCC: TIB-152), with 
wild type NPM1 genetics, was used as a negative control for the antibody 
titration experiments and was cultured using RPMI 1640 (Gibco), 10% FBS 
(Gibco). Both cell lines were grown under standard conditions: 37˚C, 5% 
CO2and 80-90% humidity. 
For the analysis of clinical samples, 5ml peripheral blood (PB) (EDTA) samples 
were collected over a three-month period from all newly diagnosed AML patients 
(no specific subtype was selected or excluded from the analysis) who had 
samples sent for flow cytometry analysis at the National Health Laboratory 
Service – Groote Schuur Hospital. A total of 12 patients were analysed. As 
clinical normal controls, 5 ml PB (EDTA) was randomly obtained from routine 
patients with normal full blood count results. Informed consent was obtained 
from each of the participants, and ethics approval was obtained from the 
University of Cape Town Ethics review board (086/2009). 
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To determine the assay sensitivity, OCI/AML3 cells were serially diluted into PB 
from the control patients (both sample types standardised to a final white cell 
count of 10 x 109/l). Dilutions ranged from 100% to 1% OCI/AML3 positive cells. 
These samples were then analysed via flow cytometry. To assess the 
reproducibility of the assay sensitivity, the 10% dilution was individually prepared 
fourteen times (dilution and sample preparation) and the samples analysed on 
two separate occasions. 
 
Overview of final developed flow cytometry assay 
Samples (cell line/ clinical samples) were diluted in phosphate buffered saline 
(PBS) to a standard nucleated cell count of 10 x 109/l (as determined using the 
Siemens Advia 2120).The samples were protected from light exposure 
throughout the antibody staining process, which involved both cell surface and 
intracellular staining. Cell surface staining was performed on 100ul of the 
prepared sample using 10ul of anti-CD45-Peridinin Chlorophyll Protein Complex 
(PerCP) (Beckton-Dickenson). After anti-CD45 incubation for 15 minutes, 
erythrocytes were lysed using 1ml FACS Lyse (Beckton-Dickenson) for 10 
minutes at RT. Samples were then washed once using 2ml 0.5% Bovine Serum 
Albumin (BSA) in PBS and the cell pellet collected via centrifugation at 400g for 
5 minutes. Cell permeabilisation with FACS perm II (0.5ml) (Beckton-Dickenson) 
was performed for 10 minutes at 4ºCand the cells were again washed once with 
0.5% BSA and the cell pellet collected as described. Optimal blocking of non-
specific binding sites was performed by re-suspending the cell pellet in 1ml of 
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3:2 ratio of human AB serum and 0.5% BSA/PBS and incubation at 37ºC for 2 
hours. The sample was then incubated with 2µl of NPM1 mutation specific 
polyclonal rabbit antihuman primary antibody (0.3mg/ml stock) (ABCAM) for 30 
minutes at room temperature. It was then washed twice using 0.5% BSA / PBS 
and re-suspended in 100µl of the 3:2 AB serum / BSA mixture. Staining with 2µl 
stock solution of secondary goat anti-rabbit antibody (Alexafluor-488 conjugate, 
Invitrogen) (0.2mg/ml) was performed for a further 30 minutes at RT. Following 
this secondary antibody labeling step, the samples were finally washed twice 
with 2ml 0.5% BSA/PBS and the cell pellet re-suspended in 1ml PBS. 
Labeled samples were analysed on a FACS Canto II instrument (Beckton 
Dickenson), which was calibrated daily using Cytometer Setup and Tracking 
beads (Beckton Dickenson). Compensation was deemed unnecessary, as 
PerCP and AlexaFluor-488 do not show spectral overlap. Analysis of raw data 
was performed with KaluzaTM software (Beckman-Coulter). To improve the 
assay sensitivity when using the clinical samples, the blasts were gated on using 
the CD45 dim and low side scatter characteristics of this cell population[20]. If 
no differentiation between granulocytes and blasts could be made, then the 
entire CD45 positive population was gated except for the lymphocytes. A 
minimum of 10 000 events was acquired in this gate.  For the analysis of all 
clinical samples, a positive control (OCI/AML3) and negative control (control PB 
acquired the same day as the AML patients) sample was simultaneously 
analysed with the AML patient samples. In the absence of clear NPM1 
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positive/negative peak differentiation, the median fluorescence intensity (MFI) of 
the NPM1 peak for the AML patients was determined and divided by the MFI of 
the NPM1 peak for the simultaneously labeled normal PB control sample (NPM1 
MFI ratio). A NPM1 MFI ratio of >1.8 was determined to correspond with NPM1 
PCR positivity. 
 
PCR analysis of NPM1 exon 12 mutation status: 
The PCR detection of NPM1 DIM was performed in the Molecular Haematology 
Diagnostic unit of the National Health Laboratory Services at Groote Schuur 
Hospital, Cape Town, using validated and SANAS accredited methodology. 
Briefly, DNA was extracted and purified from PB using the Maxwell 16 nucleic 
acid extractor (Promega, USA) and diluted to 25ng/µl with nuclease-free water 
(Promega, USA). Primers developed by Laughlin et al (2008) were used to 
amplify an 117bp fragment of exon 12 of NPM1 and a 121bp fragment 
containing the NPM1 DIM, if present - NPM1F: TTTTCCAGGCTATTCAAGATC, 
NPM1R: GGACAGCCAGATATCAACTG[21]. The following PCR conditions 
were used for the amplification on a GeneAmp 9700: 35 cycles - 95˚C/60s, 
56˚C/60s, 72˚C/60s with a final 72˚C/7mins. PCR products were diluted 1/10 
with Hi-dye formamide, mixed with ILS600 standard/Hi-Dye (Life 
technologies,USA) and separated on a POP4/37cm column using the ABI3100 
genetic analyzer (capillary electrophoresis) (Applied Biosystems, UK). 
GeneMapper 4.1(Life technologies, USA) was used to size the peaks, with a 
minimum peak height defined as 50 relative light units. Patient samples were 
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analysed in duplicate, along with DNA from OCI/AML3 (50% NPM1 DIM alleles), 
a control clinical sample (sequence confirmed) and the appropriate DNA 
extraction control. This assay was found to be able to reliably detected NPM1 




An antibody titration experiment was designed to determine the optimal primary 
and secondary antibody concentrations for the assay, which would produce the 
highest discriminatory power between the positive and negative populations. 
OCI/AML3 (positive for mutated NPM1) and Jurkat cells (negative for NPM1) 
were used in a 1:1 ratio with a final white cell count of 10x109/l. The volume of 
the primary and secondary antibodies was varied sequentially from 1 – 5μl, in 
100µl of cell mixture, until acceptable differentiation could be made between the 
positive and negative population groups. The cell mixtures were analysed by 
creating a histogram for each combination of primary and secondary antibody by 
plotting mutated NPM1 against the number of cell events. Optimum volumes of 
primary and secondary antibody were found to be: 2μl primary (final 
concentration 6 µg/ml) antibody and 2μl secondary antibody (final concentration 
7 µg/ml) in a final labeling volume of 104μl. Fig. 1 shows the optimal 








Figure 1: Optimal mutated-NPM1 detection.g 
1:1 mix of OCI/AML3 (NPM1DIM positive) and Jurkat (NPM1DIM negative) cells stained with 2μl 
of the primary antibody (anti-mutated NPM1) and 2μl of the secondary antibody (Alexafluor 488 
goat anti-rabbit) in a final reaction mixture of 104μl. Histogram shows optimal separation of 
these cell lines. 
 
 
Minimising non-specific antibody binding 
Non-specific binding and thus false positive results are common in assays using 
primary and secondary antibodies. This is mostly due to binding by Fc receptors 
on the monocytes and neutrophils [22]. While this problem was not experienced 
with the labeling of the cultured cells (due to the limited cell differentiation), 
analysis of clinical normal PB samples demonstrated a significant non-specific 
binding issue (Fig. 2A), resulting in false mutated-NPM1 positivity.  
 
Monocytes and neutrophils can either be removed from the specimen, 
systematically gated out during analysis or the Fc receptors effectively blocked 
to resolve this issue. A number of techniques are available and were attempted 
to achieve this goal. This included plastic absorption of monocytes (and thus 
removing them from the specimen), however this will not resolve the presence of 
                                                
gNote that all diagrams have been inserted into the text according to University 
of Cape Town guidelines. This is in contrast with the instruction of the author 






the neutrophils, and blocking the Fc receptor with varying concentrations ofBSA 
(0.5% - 5% in PBS) on its own or in combination with human AB Rh negative 
serum (AB serum: BSA/PBS ranged from 1:1 to 3:2) [22]. An initial attempt to 
remove the monocytes by plastic absorbance did not significantly reduce the 
number of cells showing non-specific binding and using BSA alone also had 
minimal effect (results not shown). Optimal blocking was finally achieved using a 
combination of human AB Rh negative serum and BSA 0.5%/PBS (3:2 ratio) for 
2 hours at 37ºC. Fig. 2B shows the expected mutated-NPM1 negativity in the 
control sample when using this blocking approach. 
Figure 2: Optimal blocking technique. 
A) Control PB clinical sample with primary anti-mutated NPM1 and secondary antibody (goat
anti-rabbit Alexa-488) added. Only 0.5% BSA blocking was performed on this specimen.CD45
positive population was gated on the dot plot. This population was then analysed with a
histogram of mutated-NPM1. B) Control PB clinical sample with primary anti-mutated NPM1 and
secondary antibody (Alexa-488 goat anti-rabbit) added. Blocking was performed on this
specimen usinghuman AB Rh negative serum and BSA 0.5%/PBS (3:2 ratio) for 2 hours at
37ºC. CD45 positive population was gated on the dot plot. This population was then analysed
with a histogram of mutated-NPM1.
A: Control PB clinical sample  - primary or secondary antibody added, BSA blocking only























Testing the sensitivity and reproducibility 
 
A sensitivity experiment was performed by diluting the positive control cell line 
(OCI/AML3) into PB of the normal clinical controls, to provide a more realistic 
cellular profile compared to only using a negative control cell line. The following 
dilutions were assayed in duplicate: 100%, 50%, 20%, 10% and 5%. Gating was 
performed on the entire CD45 positive population, as OCI/AML3 cells were not 
easily distinguishable from granulocytes and monocytes in these mixed 
samples. 
 
Sensitivity of the assay was established at 10%, using the mutated-NPM1 
histogram. Fig. 3 shows the results from the analysis of the 20%, 10% and 5% 
mixes. The population of NPM1 positive cells could be clearly identified at the 
10% level on the histogram (fig. 3B); however it became progressively more 
difficult to differentiate the NPM1 positive cells from the negative population at 
lower levels (fig. 3C). 
 
Reproducibility was evaluated at this sensitivity limit, by analysing fourteen 10% 
sample preparations on two separate occasions. This was performed to 
establish if the assay could reproducibly detect the NPM1 mutated cells in the 
control clinical samples. The MFI of the mutated NPM1 peak was calculated and 
showed minimal variation (see Table 1), with intra and inter-experimental 




Figure 3: Sensitivity of assay. 
(A) 20% NPM1 mutated positive control cell line mixed with clinically normal PB. CD45 positive 
population was gated on a dot plot. The histogram displays this CD45 gated population with 
mutated NPM1 (Alexa-488 positivity) vs count. The NPM1 mutated cells population was then 
gated on the histogram (gate 1) and back gating shown in a different colour on the CD45 dot 


























































10% positive control 
cells Day1 Day2 
1 39 36.87 
2 40.52 40.51 
3 37.4 36.52 
4 39.99 40.7 
5 38.96 37.16 
6 36.56 36.35 
7 37.24 36.64 
8 36.14 36.69 
9 33.3 33.29 
10 36.23 37.48 
11 41.4 36.78 
12 39.59 42.18 
13 40.26 37.8 
14 35.34 40.27 
Mean 38.00 37.80 
Standard deviation 2.32 2.32 
Coefficient of variation 6.12 6.14 
Positive control only 51.32 51.38 
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To determine the specificity and performance of the assay in a clinical setting, 
PB samples from twelve newly diagnosed AML patients were assayed for the 
NPM1 DIM using both this flow cytometry and a routine PCR assay. The PCR 
assay indicated that only 2/12 patients were positive for the exon 12 mutation 
(type not defined) (see Table 2). Both patients showed normal cytogenetics. 
For the flow cytometric analysis, patient samples were analysed on separate 
days and were co-analysed with a 100% positive control OCI/AML3 sample and 
a clinical negative control sample, to control for variation in antibody labeling 
efficiencies and instrument fluctuations.  What was immediately evident was that 
although the single peaks obtained for the PCR positive NPM1 DIM patients and 
the positive control cell line gave distinctly different MFIs compared to those of 
clinically negative control samples, the MFI of the PCR-positive patients was 
significantly different from the positive control (MFI: 23.13& 10.36 vs. 44.95) 
(shown in fig. 4). This made it difficult to use the positive control as a marker for 
determining NPM1 mutation positivity. It is postulated that this discrepancy may 
be due to the fact that the cells of the positive cell line (OCI/AML3) are much 
larger than clinically mutated blasts and have a higher fluorescence due to the 
increased content of the mutated protein; however this remains to be proven. 
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Figure 4: Clinical evaluation of AML patients and controls. 
All samples prepared using AB serum / BSA blocking methodology. Population of CD45 positive 
cells gated on dot plot of CD45 vs Side Scatter (lymphocytes excluded from analysis in patients). 
This population was then evaluated using a histogram of mutated NPM1 (Alexafluor-488) vs 
Count. The MFI of the peak was determined. A) Positive control (MFI: 44.73) B) Negative control 
(MFI: 9.38) C) PCR positive for NPM1 DIM patient (MFI: 23.1) and D) PCR negative patient 
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To more objectively indicate the NPM1 mutational state, the MFI of the ten 
NPM1 DIM-PCR negative wild type NPM1 AML patients was determined. The 
MFI of each patient single peak was normalised to the negative control, which 
had been co-analysed with each patient sample. Table 2 shows the results of 
this analysis, indicating the wild type NPM1 MFI ratio range to be 1 – 1.8 
(minimum – maximum) using the ten AML NPM1 DIM negative patients. The 
presence of the NPM1 mutated protein would therefore be indicated by a NPM1 
MFI ratio of greater than 1.8. The two PCR positive cases were subsequently 
evaluated using this methodology. Table 2 shows this result, indicating a NPM1 
MFI ratio of 2.5 for AML11 and 2.4 for AML 12, both then indicating the 
presence of the mutated NPM1 protein. Using this analysis methodology, we 
were able to get full concordance between both the PCR and flow cytometric 
assays. 
Table 2: NPM1 DIM clinical assessment – AML patient analysis 




Control MFI ratio* PCR 
MFI MFI 
AML1 8.4 27.8 7.7 1.1 Negative 
AML2 6.0 29.9 5.1 1.2 Negative 
AML3 6.4 29.9 5.1 1.3 Negative 
AML4 10.4 48.0 6.1 1.7 Negative 
AML5 10.4 48.0 6.1 1.7 Negative 
AML6 10.7 48.0 6.1 1.8 Negative 
AML7 7.8 33.7 6.9 1.1 Negative 
AML8 6.9 33.7 6.9 1.0 Negative 
AML9 6.9 33.7 6.9 1.0 Negative 
AML10 10.5 34.2 6.3 1.7 Negative 
AML11 11.3 19.8 4.7 2.4 Positive 
AML12 23.1 45.1 9.4 2.5 Positive 
#: MFI of single peak generated 
* Calculated as MFI positive peak in sample/MFI peak of clinical negative control
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Cost and analysis time: 
The comparative cost and time needed to generate a reportable patient result 
using either the PCR or flow cytometry methodology was calculated. For flow 
cytometry analysis, the costs included the preparation of a single patient tube, 
as well as a positive and negative control. A result could be generated for under 
R500 (R470.73/$45.75), within the same day as obtaining the sample (1 hour 
hands on time / 4.5 hours total). The assay does not require more labour or 
additional instrumentation compared to the standard immunophenotyping that is 
performed on all cases of acute leukaemia and can be easily incorporated into 
the routine flow cytometry on these patients without requiring additional time. 
 
The PCR analysis would include a single patient DNA extraction, PCR reactions 
of the patient DNA in duplicate, positive/negative and extraction blank PCR 
controls and fragment analysis via capillary electrophoresis. The total cost of this 
three-step process was significantly cheaper than flow cytometry, being able to 
generate a result for under R200 (R193.06/$18.39). The total time required for 
this analysis would be at least 4 hours, with a hands-on time of about 30 
minutes. While this is slightly faster than the flow cytometry, in practice this 
assay would be spread over at least two days due to the standard practice of 








Table 3:Cost analysis of the NPM1 DIM PCR and flow cytometry assays to 























FACS Perm II 16.53/1.57 PCR tubes/tips 13.36/1.27 
FACS Lyse 25.20/2.40 Formamide/ILS600 15.25/1.45 
Pipette tips/tubes 4.92/0.47 ABI analysis 100.00/9.52 
PBS 4.3/20.41   
Total 470.73/45.75 Total 193.06/18.39 
* Rand / Dollar exchange @R10.50 / $ 
 
Discussion:  
Flow cytometry is gaining importance as an alternative method to PCR for 
detection of fusion proteins in haematological malignancies [23-26]. The aim of 
the project was to develop an alternative method to PCR for specifically 
                                                
iThis table will not be included in the article and will be submitted as part of the 
appendix. This was done to comply with the IJLH restriction on figures and 
tables 
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detecting the mutated NPM1 protein utilising flow cytometry and commercially 
available reagents.  
We successfully developed and optimised an assay using positive and negative 
control cell lines to detect NPM1 DIM on flow cytometry and partially validated 
this, using clinical samples. The sensitivity of the assay was established at 10%, 
showing good reproducibility. The assay showed 100% concordance with a PCR 
assay to detect these mutations, but because of low numbers of positive 
patients requires further study and validation before it can be implemented 
diagnostically. 
Two groups have developed and tested mutated NPM1 protein specific 
antibodies for flow cytometry [17,18], however the antibodies that were used are 
not yet commercially available. The studies demonstrated variable success, with 
the antibody from Gruszka’s research group [17]showing high specificity for 
mutated NPM1 protein, but the other from Tan et al [18] showing significant 
cross reactivity with WT NPM1 protein. While both research groups used 
secondary antibodies to detect the antibody to mutated NPM1 protein [17,18], 
Tan et al [18] only tested the antibody’s performance on an 
immunohistochemistry platform using a peroxidase labeled secondary antibody 
without blocking steps to prevent non-specific binding. Gruszka et al [17] tested 
their antibody on multiple platforms including flow cytometry and utilising purified 
IgG1 for the purpose of blocking. This study was therefore in agreement with 
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ours that it is essential to block the cells before secondary-antibody labelling to 
ensure NPM1-labelling specificity. 
 
Gruszka et al [17] found the sensitivity of their assay to be as sensitive as 
0.001%, however this was performed using positive and negative cell line (HL60 
and OCI/AML3) mixtures, which does not simulate the normal scenario faced 
when dealing with clinical specimens containing a range of different cell types 
(including red cells). This is in contrast to the sensitivity limit established in our 
study; however our experiments were conducted using normal PB as the NPM1 
WT specimen (diluting factor) and therefore more likely represents the sensitivity 
in the clinical setting. Sensitivity of the assay was deemed to be acceptable at 
10%, as most diagnostic AML samples will contain in excess of 20% blasts [1]. 
However, this technique cannot be used for residual disease monitoring post-
transplant or therapy where a much higher sensitivity is required (reviewed by 
Paietta [27]).  
 
The assay presented here however requires further validation as only a small 
number of AML patients with NPM1 DIM were tested. It is envisaged that at 
least 20 additional patients with AML with eight showing positivity, will be 
required to ensure the validity of this assay. This will also mean that a larger 
selection of NPM1 DIM subtypes is evaluated. Unfortunately the PCR 
methodology used in this study cannot differentiate the different subtypes of 
NPM1 DIM. This may pose a hurdle in future studies when there is discordance 
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between the PCR and the flow cytometry assay, to establish which subtypes 
were not detected (if applicable). Unfortunately due to lack of funding more 
patient samples could not be performed at this time. 
 
The presence of NPM1 DIM in patients with AML is strongly associated with a 
normal cytogenetic karyotype [28]. Cytogenetic analysis is a labour intensive 
process with long turn-around times and is costly[29]. No cases of AML with a 
NPM1 mutation have ever been shown to have recurrent cytogenetic 
abnormalities as described in the WHO[28], potentially obviating the need to 
perform cytogenetics when this mutation is present. Immediate information 
relating to the mutational status of NPM1 can thus assist in decision making to 
process cytogenetics or not, leading to cost saving. This may also be an 
advantage for laboratories without a laboratory to process cytogenetics and 
need to transport samples over great distances to gain access to these facilities 
often resulting in failure of the assay due to age of the specimens [29]. Although 
the cost of the assay is somewhat more than that of PCR, one must take into 
account the additional labour specifically required to perform the PCR. No 
additional personal or equipment is required to perform the flow cytometry in a 
laboratory where these functions have already been established. The flow 
cytometry assay delivers same day results and patient management may 
potentially be commenced faster. 
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In summary, we have developed and partially validated a flow cytometry assay 
to detect NPM1 DIM at the translational level by using commercially available 
reagents. This assay should be reproducible in any laboratory with expertise in 
flow cytometry but requires further validation. 
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PART D: SUPPORTING DOCUMENTATION 





I, _________________  hereby give consent that a sample of my bone marrow may be 
used in the development of a new laboratory technique for the determination of 
Nucleophosmin mutational status, a protein involved in the cause and prognosis of 
leukaemia. Studies will be conducted at the National Health Laboratory Service – 
Groote Schuur Hospital.   
The samples will be anonymous and will not affect your diagnosis or treatment at all. 
I understand that I may withdraw my consent for any aspect of the above study at any 
time without affecting my future medical care. 
All of the above have been explained to me in a language that I understand and my 
questions have been answered. 




Informed consent obtained by: __________________ 
Signature: ____________________ 
86 
Annexure C:  
International Journal of Laboratory Hematology: Author Guidelines 
The journal provides an international forum for all new developments in the 
research and practice of laboratory hematology and includes invited reviews, full 
length original articles, and correspondence. 
Article Submission 
Online Submission 
Papers (in English) should be submitted online at 
http://mc.manuscriptcentral.com/ijlh. Authors will need their entire manuscript in 
electronic format. Full instructions, a user ID and password are available at the 
site. Technical support for submission can be obtained by e-mailing 
support@scholarone.com or by telephoning +1 434 817 2040 ext 167. 
Authors unable to submit their manuscript online should contact the IJLH 
Editorial Office: 
Email: delia@malimrobin.co.uk 
Tel: +44 (0)1603 278046 
The journal to which you are submitting your manuscript employs a plagiarism 
detection system. By submitting your manuscript to this journal you accept that 
your manuscript may be screened for plagiarism against previously published 
works.  
Copyright Transfer Agreement 
If your paper is accepted, the author identified as the formal corresponding 
author for the paper will receive an email prompting them to login into Author 
Services; where via the Wiley Author Licensing Service (WALS) they will be able 
to complete the license agreement on behalf of all authors on the paper. 
For authors signing the copyright transfer agreement 
If the OnlineOpen option is not selected the corresponding author will be 
presented with the copyright transfer agreement (CTA) to sign. The terms and 
conditions of the CTA can be previewed in the samples associated with the 
Copyright FAQs below: 
CTA Terms and Conditions 
http://authorservices.wiley.com/bauthor/faqs_copyright.asp 
For authors choosing OnlineOpen 
If the OnlineOpen option is selected the corresponding author will have a choice 
of the following Creative Commons License Open Access Agreements (OAA): 
Creative Commons Attribution Non-Commercial License OAA 
Creative Commons Attribution Non-Commercial -NoDerivs License OAA  
87 
To preview the terms and conditions of these open access agreements please 
visit the Copyright FAQs hosted on Wiley Author Services 
http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit 
http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--
License.html. 
If you select the OnlineOpen option and your research is funded by The 
Wellcome Trust and members of the Research Councils UK (RCUK) you will be 
given the opportunity to publish your article under a CC-BY license supporting 
you in complying with Wellcome Trust and Research Councils UK requirements. 
For more information on this policy and the Journal’s compliant self-archiving 
policy please visit: http://www.wiley.com/go/funderstatement. 
For RCUK and Wellcome Trust authors click on the link below to preview the 
terms and conditions of this license: 
Creative Commons Attribution License OAA  
To preview the terms and conditions of these open access agreements please 
visit the Copyright FAQs hosted on Wiley Author Services 
http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit 
http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--
License.html. 
Note to NIH Grantees 
Pursuant to NIH mandate, Wiley Blackwell will post the accepted version of 
contributions authored by NIH grant-holders to PubMed Central upon 
acceptance.  This accepted version will be made publicly available 12 months 
after publication.  For further information, see www.wiley.com/go/nihmandate. 
Types of articles 
Original Articles 
Articles should be no longer than 4000 words, contain not more than 40 
references, not more than five figures/tables and include a structured abstract. 
Review Articles 
These are normally invited contributions but suitable papers may be submitted 
to the Editor for consideration for this purpose. Articles should be no longer than 
5000 words, contain not more than 60 references, not more than six 
figures/tables and include a summary of up to 250 words.  
Letters to the Editor 
Correspondence which relates to papers which have recently appeared in the 
journal may be published. The Editor reserves the right to invite response from 
the original authors for publication alongside. In addition, letters dealing with 
88 
more general scientific matters of interest to haematologists will be considered; 
such letters will be published online only and will not appear in the printed 
edition of the journal, although they will be listed in the Table of Contents. 
Letters should be as short as possible (but no more than 1,500 words of text, 
two figures or tables or one of each, and up to 10 references). 
Correspondence to the journal is accepted on the understanding that the 
contributing author licenses the publisher to publish the letter as part of the 
journal or separately from it, in the exercise of any subsidiary rights relating to 
the journal and its contents.  
Case Reports 
Case Reports will not be accepted unless they are of exceptional interest, and 
may be submitted as correspondence. 
Presentation of Manuscripts 
The manuscript should be double-spaced with 30mm margins. Manuscripts 
must be numbered consecutively in the following sequence:  Title Page; 
Abstract (if required);  Main Body of Text;  Acknowledgements;  Reference List; 
Tables and Figure caption List.  
1. Title page
The title page should contain the authors name(s), initials and place of work. In
addition, the name and full postal address including e-mail, of the author who
will deal with correspondence and proofs should be supplied. The full title should
be accompanied by a short running title where the title exceeds 47 letters and
spaces. In the top right hand corner, the number of manuscript pages and
illustrations should be marked. Five keywords should be supplied after the
Summary.
2. Abstract
A structured abstract of no more than 200 words is required for original articles,
subdivided into the following sequential sections: Introduction; Methods; Results;
Conclusion.
3. Main body of text
The text of original and review articles should be divided into the following
sections: Introduction, Materials and methods, Results, Discussion, Tables,
Footnotes and Figure legends (including magnifications).
4. Acknowledgments
Acknowledgements should be submitted on a separate sheet.
5. References
We recommend the use of a tool such as Reference Manager for reference
89 
management and formatting. Reference Manager reference styles can be 
searched for here: http://www.refman.com/support/rmstyles.asp 
The reference list should be in the Vancouver style, with references numbered 
consecutively in the order in which they first appear in the text. List all authors. 
Within the text itself, references should be cited by number in square brackets. 
Authors are responsible for the accuracy of their references. 
1. Standard Journal Article
Rice S, Slater DN, Hewer EM. The effect of nonscreening smears on screening
smear results: a statistical analysis with its implications for the NHS cervical
screening programme. Cytopathology 2000;11:158-65.
2. Journal Supplement
Baskin-Bey ES, Morono Luna LE, Gores GJ. Diagnosis of cholangiocarcinoma
in patients with PSC: a sight on cytology. J Hepatol 2006;45(Suppl.1):12-14.
3. Editor, compiler, chairman as author
Dausset J, Colombani J, eds. Histocompatibility Testing. Copenhagen:
Munksgaard; 1973: 12-8.
4. Chapter in a book
Weinstein L, Swartz MN. Pathogenic properties of invading microorganisms. In:
Pathologic Physiology: Mechanisms of Disease, 6th edn. Sodeman WA Jr.
Sodeman WA. (eds). Philadelphia: WB Saunders; 1974: 457-72.
6. Tables and figures
The preferred position of figures and tables in the text should be indicated in the
left-hand margin. Tables should include only essential data. Each table should
be typewritten on a separate sheet and must be numbered consecutively with
Arabic numerals, e.g. Table 1, and given a short caption. Vertical rules should
not be used. Units should appear in parentheses in the column headings and
not in the body of the table. All abbreviations should be defined in a footnote.
All tables and figures that are reproduced from a previously published source 
must be accompanied by a letter of permission from the publisher or copyright 
owner. 
Illustrations: Photographs will be printed un-reduced where possible but should 
not exceed 250 × 170 mm and authors may be asked to contribute to the cost of 
printing if the space requested for illustrations is considered excessive. In the 
case of electron micrographs it is desirable that full page width should be 
utilized. 
Authors are encouraged to visit our updated artwork guidelines for more 
information on preparation of high resolution figures. 
90 
Colour: Authors will be asked to contribute towards the cost of reproduction of 
colour figures. Please note that if there is colour artwork in your manuscript 
when it is accepted for publication, Wiley Blackwell require you to complete and 
return a colour work agreement form before your paper can be published. 
If you are unable to download the form, please contact the Production Editor at 
ijlh@wiley.com for a form to be sent to you by email or fax. Any article received 
by Wiley Blackwell with colour work will not be published until the form has been 
received. 
Authors who would like to have their figures printed in colour have to fill in their 
credit card details in the form and post or courier it to: 
Customer Services (OPI), John Wiley & Sons Ltd, European Distribution Centre, 
New Era Estate, Oldlands Way, Bognor Regis, West Sussex PO22 9NQ 
In the event that an author is not able to cover the costs of reproducing colour 
figures in colour in the printed version of the journal, International Journal of 
Laboratory Hematology offers authors the opportunity to reproduce colour 
figures in colour for free in the online version of the article (but they will still 
appear in black and white in the print version). If an author wishes to take 
advantage of this free colour-on-the-web service, they should liaise with the 
Editorial Office to ensure that the appropriate documentation is completed for 
the Publisher.  
7. Units and Spelling
Spelling should conform to The Concise Oxford Dictionary of Current English
and units of measurement, symbols and abbreviations with those in Units,
Symbols and Abbreviations published and supplied by the Royal Society of
Medicine, 1 Wimpole Street, London W1M 8AE. Units should follow the SI
system except where earlier conventions persist (e.g. Hb in g/dl).
Fractions of unity and thousands: The traditional and scientific method for 
indicating the breakpoint between unity and fractions of unity has been the 
decimal point. Recently the market trader conversion of using a comma to divide 
whole monetary units from fractions thereof has begun to pervade some 
scientific literature. International Journal of Laboratory Hematology will continue 
to use the scientific convention of a decimal point to indicate the break between 
unity and decimal fractions. 
International Journal of Laboratory Hematology will use the well-established 
scientific convention of the thin space as a means of dividing large numbers into 




If you have previously provided Supporting Information with your article, please 
note it will not be edited or altered from its original format during the Production 
process. Although a proof of your Supporting Information is not available, it will 
appear online when your article is published.  
Publication Ethics 
Please read the Ethical Policies of IJLH prior to submitting to the Journal. 
Disclosure and Competing Interests Statements 
Authors are required to disclose financial interests in any company or institution 
that might benefit from their publication. A competing interest exists when a 
primary interest (such as patients’ welfare or the validity of research) might be 
influenced by a secondary interest (such as financial gain or personal rivalry). It 
may arise for the authors of an International Journal of Laboratory Hematology 
article when they have a financial interest that may influence their interpretation 
of their results or those of others. Financial interests are the easiest to define 
and they have the greatest potential to influence the objectivity, integrity or 
perceived value of a publication. They may include any or all, but are not limited 
to, the following:  
• Personal financial interests: Stocks or shares in companies that may gain or
lose financially through publication; consultant fees or fees from speakers
bureaus other forms of remuneration from organisations that may gain or lose
financially; patents or patent applications whose value may be affected by
publication.
• Funding: Research support from organisations that might gain or lose
financially through publication of the paper.
• Employment: Recent, present or anticipated employment of you or a family
member by any organization that may gain or lose financially through publication
of the paper. Any such competing interest that authors may have should be
declared. The aim of the statement is not to eradicate competing interests, as
they are almost inevitable. Papers will not be rejected because there is a
competing interest, but a declaration on whether or not there are competing
interests will be added to the paper.
• Patent rights
• Consultancy work.
All authors must disclose competing interests, or state “none” via the Journal's 
ScholarOne Manuscripts website.  
All sources of funding must be disclosed in the Acknowledgments section of the 
paper. List governmental, industrial, charitable, philanthropic and/or personal 
sources of funding used for the studies described in the manuscript. Attribution 
of these funding sources is preferred. Examples:  
92 
• This work was supported by a grant from the National Institutes of Health, USA
(DKxxxx to AB).
• This work was supported by the Crohn's and Colitis Foundation of Canada
(grant to AB and CD).
• This work was supported by a grant from Big Pharma Inc. (to AB) and
equipment was donated by Small Pharma Inc. EF received a graduate
studentship award from the University of xxxxx.
For papers where there are no competing interests, all authors must include the 
statement ‘Competing interests: the authors have no competing interests.’ We 
will also ask reviewers to provide a statement of competing interests.  
Authorship 
All authors must fulfil the following three criteria: 
• Substantial contributions to research design, or the acquisition, analysis or
interpretation of data,
• Drafting the paper or revising it critically, and
• Approval of the submitted and final versions.
In the Acknowledgments section of the paper all authors, must indicate their 
specific contributions to the work described in the manuscript. Some examples 
include:  
• X performed the research
• Y designed the research study
• Z contributed essential reagents or tools
• A analysed the data • B wrote the paper.
An author may list more than one contribution, and more than one author may 
have contributed to the same element of the work. E.g. ‘A performed the 
research, A and C analysed the data and wrote the paper, E contributed the 
knockout mice for the study and G designed the research study and wrote the 
paper’.  
Role of professional medical writers in peer-reviewed publications 
Please ensure that you follow the guidelines by the European Medical Writers 
Association on the role of medical writers. The guidelines emphasise the 
importance of respecting widely recognised authorship criteria, and in particular 
of ensuring that all people listed as named authors have full control of the 
content of papers. The role of professional medical writers must be transparent. 
Please name any professional medical writer among the list of contributors to 
any article for International Journal of Laboratory Hematology (not only original 
research papers), and specify in the acknowledgements and statement of 
competing interests for the article who paid the writer. 
93 
Author Services 
Online production tracking for your article 
Author Services enables authors to track their article - once it has been 
accepted- through the production process to publication online and in print. 
Authors can check the status of their articles online and choose to receive 
automated e-mails at key stages of production so they don't need to contact the 
production editor to check on progress. The author will receive an e-mail with a 
unique link that enables them to register and have their article automatically 
added to the system. Please ensure that a complete e-mail address is provided 
when submitting the manuscript. Visit http://authorservices.wiley.com/bauthor/ 
for more details on online production tracking and a wealth of resources 
including FAQs and tips on article preparation, submission and more. 
Pre-submission English-language editing 
Authors for whom English is a second language may choose to have their 
manuscript professionally edited before submission to improve the English. A list 
of independent suppliers of editing services can be found at 
http://authorservices.wiley.com/bauthor/english_language.asp. All services are 
paid for and arranged by the author, and use of one of these services does not 
guarantee acceptance or preference for publication. 
PDF proofs 
The corresponding author will receive an email alert containing a link to a web 
site where the proofs can be downloaded as an Acrobat PDF; in your absence, 
please arrange for a colleague to access your e-mail to retrieve the proofs. 
Corrections should be returned within 2 weeks of receipt. Alterations in the text, 
other than corrections, may be charged to the author. 
Offprints 
A PDF offprint of the online published article will be provided free of charge to 
the corresponding author, and may be distributed subject to the Publisher's 
terms and conditions. Paper offprints of the printed published article may be 
purchased if ordered via the method stipulated on the instructions that 
accompany the proofs. Printed offprints are posted to the correspondence 
address given for the paper unless a different address is specified when 
ordered. Note that it is not uncommon for printed offprints to take up to eight 
weeks to arrive after publication of the journal. 
Electronic offprints are sent to the first author at his or her first email address on 
the title page of the paper, unless advised otherwise; therefore please ensure 
that the name, address and email of the receiving author are clearly indicated on 
the manuscript title page if he or she is not the first author of the paper. 
Early View 
IJLH  is covered by our Early View service, which means that, once we have 
94 
received your corrections, your article will be published online without having to 
wait for inclusion in a print issue. Please note that the version of your paper that 
appears online is complete and final, except for volume, issue and page 
numbers, which are added upon print publication. Therefore, there will be no 
further opportunity to make changes to your article after online publication. 
Author material archive policy: Please note that unless specifically requested, 
Wiley Blackwell will dispose of all hard copy or electronic material submittted two 
months after publication. If you require the return of the material submitted, 
please inform the editorial office or production editor as soon as possible if you 
have not yet done so. 
Revised Author Guidelines – July 2013 
95 
Annexure D 
96 
97 
98 
99 
